Sangui Biotech International Inc (SGBI) financial statements (2022 and earlier)

Company profile

Business Address 352 SOUTH 200 WEST
FARMINGTON, UT 84025
State of Incorp. CO
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
TTM
6/30/2021
6/30/2020
6/30/2019
6/30/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments830152721
Cash and cash equivalents830152721
Receivables31231735 
Prepaid expense161213921
Other undisclosed current assets 23760
Total current assets:56674979102
Noncurrent Assets
Property, plant and equipment112  
Other undisclosed noncurrent assets786675  
Total noncurrent assets:796777  
TOTAL ASSETS:13513412579102
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Debt767753619478 
Due to related parties69624228 
Other liabilities1    
Other undisclosed current liabilities147140131164453
Total current liabilities:984955791671453
Noncurrent Liabilities
Long-term debt and lease obligation535564  
Operating lease, liability535564
Other undisclosed noncurrent liabilities(53)(55)(64)  
Total noncurrent liabilities:535564  
Total liabilities:1,0371,009855671453
Stockholders' equity
Stockholders' equity attributable to parent, including:(250)(224)(83)49(351)
Common stock33,10033,08833,02832,96732,864
Treasury stock, value(19)(19)(19)(19)19
Additional paid in capital4,5134,5134,5134,5134,513
Accumulated other comprehensive income8990929193
Accumulated deficit(37,932)(37,895)(37,696)(37,504)(37,180)
Other undisclosed stockholders' equity attributable to parent    (661)
Stockholders' equity attributable to noncontrolling interest(653)(652)(647)(641) 
Total stockholders' equity:(902)(875)(730)(592)(351)
TOTAL LIABILITIES AND EQUITY:13513412579102

Income statement (P&L) ($ in thousands)

12/31/2021
TTM
6/30/2021
6/30/2020
6/30/2019
6/30/2018
Revenues7666298877
Cost of revenue
(Cost of Goods and Services Sold)
    (0)
Gross profit:7666298877
Operating expenses(207)(217)(210)(426)(285)
Operating loss:(132)(151)(181)(338)(208)
Nonoperating income (expense)41(53)(17)(5) 
Foreign currency transaction gain (loss), before tax60(35)47 
Interest and debt expense(23)(18)(14)(12)8
Loss from continuing operations before equity method investments, income taxes:(114)(222)(213)(354)(200)
Other undisclosed loss from continuing operations before income taxes    (16)
Loss before gain (loss) on sale of properties:(114)(222)(213)(354)(216)
Other undisclosed net income23181412 
Net loss:(91)(204)(199)(343)(216)
Other undisclosed net income (loss) attributable to parent35619(29)
Net loss available to common stockholders, diluted:(87)(199)(193)(324)(245)

Comprehensive Income ($ in thousands)

12/31/2021
TTM
6/30/2021
6/30/2020
6/30/2019
6/30/2018
Net loss:(91)(204)(199)(343)(216)
Other comprehensive income93206198344 
Comprehensive income (loss), net of tax, attributable to parent:22(0)1(216)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: